Interim Analysis of the Lymphedema “PREVENT” Randomized Trial

Presenting Author: Sheila H. Ridner, PhD, RN
Co-Authors: Mary S. Dietrich, PhD, Michael S. Cowher, MD, Bret Taback, MD, Sarah McLaughlin, MD, Nicolas Ajkay, MD, John Boyages MD, PhD, Louise Koelmeyer, BAppSc(OT), Sarah M. DeSnyder, MD, Jamie Wagner, DO, Vandana Abramson, MD, Andrew Moore, MD, Chirag Shah, MD
Disclosures

• Dr. Ridner is employed by Vanderbilt University. She serves as Principal Investigator for studies funded by ImpediMed Inc. and Tactile Medical through contractual agreements between the companies and Vanderbilt University.

• Data presented are from a study funded by ImpediMed Inc. with
  – In-kind donations of garments from medi, and
  – REDCap data capture system funded by National Institutes of Health (NIH/NCATS UL1 TR000445)
Background

• Despite advances in breast conserving surgery, radiation protocols, and chemotherapy, breast cancer-related lymphedema remains a major source of morbidity and concern in the patient population.

• Prospective surveillance model gaining support
  – Research is needed to compare lymphedema risk reduction outcomes resulting from standard assessment method (tape measure) to those from bioelectrical impedance spectroscopy (BIS).

• Aim: To determine if subclinical detection of extracellular fluid accumulation via bioelectrical impedance spectroscopy (BIS) and subsequent early intervention reduce the rate of progression to CDP relative to rates seen using standard tape measurement (TM).
Methods

- Design: international, multi-site, two-group (Tape Measure and Bioelectrical Impedance Spectroscopy), randomized controlled trial
- Population: newly diagnosed breast cancer patients
  - Stage I-III invasive breast cancer or DCIS with at least one of the following: mastectomy, axillary treatment (axillary lymph node dissection, sentinel lymph node biopsy with greater than 6 nodes, axillary radiation), taxane based chemotherapy
- Post surgical follow-ups
  - 3 months, 6 months, 12 months, 15 months*, 18 months, 21 months*, 24 months, 30 months and 36 months
  - *optional visit
Methods

- **Trigger Points**
  - Tape measure $\geq 5\%-<10\%$ volume change from pre-treatment baseline
  - BIS $\geq 6.5$ L-Dex change from pre-treatment baseline
- **Intervention**
  - compression sleeve and gauntlet for 4 weeks, 12 hrs. a day
- **Progression** $\geq 10\%$ volume change from pretreatment baseline as measured by tape measure
Interim Analysis-required when ≥ 500 patients completed 12 months of follow-up

<table>
<thead>
<tr>
<th></th>
<th>Tape Measurement</th>
<th>BIS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Sample</td>
<td>N=508</td>
<td>N=245</td>
</tr>
<tr>
<td>Sample for Potential Trigger</td>
<td>N=498</td>
<td>N=239</td>
</tr>
<tr>
<td></td>
<td>n (%)</td>
<td>n (%)</td>
</tr>
<tr>
<td>Triggered</td>
<td>109 (21.9%)</td>
<td>68 (28.5%)</td>
</tr>
<tr>
<td>Progression</td>
<td>12 (11.0%)</td>
<td>10 (14.7%)</td>
</tr>
</tbody>
</table>
Conclusions

• Interim results of post-treatment surveillance with BIS of lymphedema progression compared to tape measure demonstrate:
  – 10% absolute reduction
  – 67% relative reduction

• Interim results may support the concept of post-treatment surveillance using BIS for early detection of subclinical lymphedema coupled with early intervention.